Holen Sie sich die Stockscreener-App
28.37
0.55%
0.2316
Schlusskurs vom Vortag:
$28.14
Offen:
$28.25
24-Stunden-Volumen:
492.44K
Relative Volume:
0.48
Marktkapitalisierung:
$1.69B
Einnahmen:
$66.05M
Nettoeinkommen (Verlust:
$-422.60M
KGV:
-3.9128
EPS:
-7.251
Netto-Cashflow:
$-384.73M
1W Leistung:
+2.04%
1M Leistung:
+11.75%
6M Leistung:
-2.57%
1J Leistung:
-5.05%
1-Tages-Spanne:
$27.51
$28.43
1-Wochen-Bereich:
$27.51
$29.10
52-Wochen-Spanne:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Firmenname
Agios Pharmaceuticals Inc
Sektor
Branche
Telefon
617-649-8600
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
28.39 | 1.67B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
436.71 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.47 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.47 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.15 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.77 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Bestätigt | H.C. Wainwright | Buy |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-27 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-17 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-02-15 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-04-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-02-15 | Bestätigt | Needham | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-10 | Bestätigt | Needham | Buy |
| 2017-08-08 | Bestätigt | SunTrust | Buy |
| 2017-08-02 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Herabstufung | Janney | Buy → Neutral |
| 2017-01-17 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Eingeleitet | Needham | Buy |
| 2016-06-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Bestätigt | SunTrust | Buy |
Alle ansehen
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe - TradingView
Agios Pharmaceuticals Gains EU Approval for PYRUKYND in Adult Thalassaemia - World Business Outlook
Agios, Partner von Avanzanite Bioscience, gibt die Zulassung von PYRUKYND® (Mitapivat) in der Europäischen Union für Erwachsene mit Thalassämie bekannt - The Joplin Globe
Agios Pharmaceuticals (AGIO) Secures EU Approval for PYRUKYND - GuruFocus
EU approves mitapivat for thalassaemia treatment in adults - Investing.com UK
EU approves mitapivat for thalassaemia treatment in adults By Investing.com - Investing.com Nigeria
Avanzanite Bioscience's partner Agios announces Pyrukynd® (mitapivat) approval in EU - marketscreener.com
Agios Gets EU Approval for Pyrukynd in Thalassemia - Moomoo
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia - standard-journal.com
New oral thalassemia drug PYRUKYND approved for adults in EU - Stock Titan
Agios' Pyrukynd® (mitapivat) approved in the European Union for adults with thalassemia - marketscreener.com
Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia - The Manila Times
Agios Pharmaceuticals Receives EU Approval for PYRUKYND® as First Medicine for Thalassemia Treatment in Adults - Quiver Quantitative
(AGIO) Volatility Zones as Tactical Triggers - Stock Traders Daily
Agios Pharmaceuticals touts strong AQVESME launch as sickle cell filing advances - MSN
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances - TradingView
Agios Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
AGIO beats on Q1 earnings & sales, stock up 13% on new drug momentum - MSN
Why is Agios Pharmaceuticals stock surging Tuesday afternoon? - MSN
Agios plans Q2 sNDA filing for mitapivat in sickle cell disease while citing >$10B 2030 market opportunity - MSN
How Investors Are Reacting To Agios Pharmaceuticals (AGIO) FDA Bid For Mitapivat In Sickle Cell Disease - Sahm
Armistice Capital (NASDAQ: AGIO) holds 2.716M shares, 4.57% stake - Stock Titan
Assessing Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Volatility - Yahoo Finance
How Agios’ Mitapivat sNDA And New SCD Trial Design At Agios Pharmaceuticals (AGIO) Has Changed Its Investment Story - Yahoo Finance
Developer seeking FDA’s accelerated approval for mitapivat for SCD - Sickle Cell Disease News
TradingKey - TradingKey
Agios sNDA And EHA Plenary Put Mitapivat At Center Of Valuation - Yahoo Finance
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease - The Globe and Mail
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $41 - Moomoo
Agios Pharmaceuticals (AGIO) Showcases Promising Mitapivat Data at EHA 2026 - GuruFocus
Agios submits application for mitapivat in sickle cell disease - Investing.com UK
Agios presents mitapivat data at European hematology congress By Investing.com - Investing.com Australia
Agios submits application for mitapivat in sickle cell disease By Investing.com - Investing.com Australia
Agios presents mitapivat data at European hematology congress - Investing.com
Agios Pharmaceuticals to Present RISE UP Phase 3 Trial Results of Mitapivat in Sickle Cell Disease at EHA 2026 Plenary Session - Quiver Quantitative
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease - The Manila Times
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias - The Manila Times
New pill for sickle cell moves to FDA review, aims to cut transfusions - Stock Titan
Oral drug lifts hemoglobin in sickle cell and thalassemia trial - Stock Titan
Price-Driven Insight from (AGIO) for Rule-Based Strategy - Stock Traders Daily
47,414 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by State of New Jersey Common Pension Fund D - MarketBeat
Number of shareholders of Agios Pharmaceuticals, Inc. – TRADEGATE:8AP - TradingView
Lynx1 (AGIO) discloses 5.1% stake — 3.01M shares reported - Stock Titan
Need To Know: Analysts Are Much More Bullish On Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenues - 富途牛牛
Agios Pharmaceuticals Stock Rises 11.2% on Strong Q1 2026 Aqvesme Launch and Pipeline Progress - IndexBox
Agios Pharmaceuticals (AGIO) Is Up 11.2% After Rare Disease Launch And FDA Acceleration NewsHas The Bull Case Changed? - Sahm
Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Agios Pharmaceuticals Inc-Aktie (AGIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Burns James William | Chief Legal Officer |
Apr 02 '26 |
Sale |
34.71 |
3,280 |
113,849 |
49,306 |
| Gheuens Sarah | Chief Medical Officer |
Apr 02 '26 |
Option Exercise |
0.00 |
8,500 |
0 |
83,217 |
| Gheuens Sarah | Chief Medical Officer |
Apr 02 '26 |
Sale |
34.71 |
2,940 |
102,047 |
80,277 |
| Jones Cecilia | Chief Financial Officer |
Apr 02 '26 |
Option Exercise |
0.00 |
8,500 |
0 |
58,139 |
| Jones Cecilia | Chief Financial Officer |
Apr 02 '26 |
Sale |
34.71 |
3,141 |
109,024 |
54,998 |
| Milanova Tsveta | Chief Commercial Officer |
Apr 02 '26 |
Option Exercise |
0.00 |
8,500 |
0 |
50,091 |
| Milanova Tsveta | Chief Commercial Officer |
Apr 02 '26 |
Sale |
34.71 |
3,262 |
113,224 |
46,829 |
| Viswanadhan Krishnan | Chief Corp Dev & Strategy |
Apr 02 '26 |
Option Exercise |
0.00 |
8,100 |
0 |
13,241 |
| Viswanadhan Krishnan | Chief Corp Dev & Strategy |
Apr 02 '26 |
Sale |
34.71 |
2,959 |
102,707 |
10,282 |
| Goff Brian | Chief Executive Officer |
Apr 02 '26 |
Option Exercise |
0.00 |
39,028 |
0 |
191,104 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):